Keyword: Sovaldi

Johnson & Johnson has notched a deal with Arcturus Therapeutics to help with its new focus on hepatitis B.

The anticipated haul will fund late-phase trials of NuCana’s reformulated cancer candidates, including a version of Eli Lilly’s Gemzar.

The deal continues the retreat from infectious diseases Medivir began after Gilead and others cornered the hepatitis C market.

Chinese CRO Newsummit Biopharma has received a license to a hepatitis C antibody from MRC Technology, a medical research charity.

Although a little late to the game, AbbVie is touting impressive cure rates for its new daily hep C combo as it looks to find a bigger wedge in a market dominated by Gilead.